<!DOCTYPE HTML>

<html>
<head>
<title> Summary + Date</title>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1, user-scalable=no" name="viewport"/>
<link href="assets/css/sum_pg.css" rel="stylesheet"/>
</head>
<!-- Google tag (gtag.js) -->
<script async="" src="https://www.googletagmanager.com/gtag/js?id=G-K51JJ2RCJJ"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'G-K51JJ2RCJJ');
</script>
<body class="is-preload">
<!-- Header -->
<header id="header">
<h1 style="margin-top: 0 !important; padding-top: 0 !important;">MAD MONEY Summaries</h1>
<!-- <p>AI-generated summaries for the show Mad Money hosted by Jim Cramer. -->
<h2 id="show_date_append_here"> Show Date: January 14, 2025</h2>
<p id="append_audio_link_here"> <a href="https://www.youtube.com/watch?v=8ifxIWjUUaw">Listen to the audio here</a></p>
</header>
<!-- Place acc summary here -->
</body>
<body id="append_here">
<h1>Jim Cramer's Show Recap</h1>
<h2>Segment 1: Introduction and Merck Discussion</h2>
<ul>
<li>Discussion with Merck's CEO, Rob Davis, highlighting the company's diversified portfolio and growth prospects.</li>
<li>Merck's Gardasil vaccine for HPV-related cancers has a global reach and potential for growth, with a goal of achieving $11 billion in sales by 2030.</li>
<li>The company is expanding Gardasil's reach, particularly in China, and working on GLP-1 drugs, including an oral small molecule GLP-1.</li>
<li>Merck's stock has been a laggard, but Cramer believes it has potential for long-term growth.</li>
<li>Key takeaway for retail investors: Consider Merck's diversified portfolio and growth prospects, particularly in the vaccine and GLP-1 spaces.</li>
</ul>
<h2>Segment 2: Regeneron Pharmaceuticals Discussion</h2>
<ul>
<li>Discussion with Regeneron's CEO, Dr. Len Schleifer, highlighting the company's history and success with blockbuster drugs Eylea and Dupixent.</li>
<li>Regeneron's pipeline has 40 drugs in development, addressing markets worth an aggregate of $200 billion, with a focus on innovation and long-term growth.</li>
<li>The company's cancer treatment has shown promising results, including a 68% reduction in the risk of recurrence for patients with squamous cell cutaneous carcinoma.</li>
<li>Cramer believes Regeneron's stock has been unfairly punished and has potential for long-term growth.</li>
<li>Key takeaway for retail investors: Consider Regeneron's strong pipeline and growth prospects, particularly in the oncology space.</li>
</ul>
<h2>Segment 3: Lightning Round</h2>
<ul>
<li><strong>Starbucks:</strong> Cramer recommends buying for the long-term trust, citing the company's strong brand and growth prospects.</li>
<li><strong>Dutch Bros:</strong> Cramer recommends buying, but warns of high valuation, citing the company's strong growth prospects and competitive advantage.</li>
<li><strong>Armored Shipping:</strong> Cramer recommends selling due to the episodic nature of the business, citing the company's volatility and lack of growth prospects.</li>
<li><strong>Super Micro Computer:</strong> Cramer recommends selling due to accounting irregularities, citing the company's lack of transparency and potential for further declines.</li>
<li><strong>FMC Corporation:</strong> Cramer recommends holding, but warns of the sector's challenges, citing the company's diversified portfolio and growth prospects.</li>
</ul>
<h2>Segment 4: Cardinal Health Discussion</h2>
<ul>
<li>Discussion with Cardinal Health's CEO, Jason Hollar, highlighting the company's expansion beyond its traditional role as a middleman in the pharmaceutical industry.</li>
<li>Cardinal Health's proprietary businesses, including GI Alliance and oncology platforms, offer high-margin growth opportunities.</li>
<li>The company's use of artificial intelligence improves customer service and efficiency, driving long-term growth.</li>
<li>Cardinal Health's management of the loss of its second-largest customer, OptumRX, demonstrates the company's resilience and ability to adapt.</li>
<li>Key takeaway for retail investors: Consider Cardinal Health's diversified portfolio, high-margin growth opportunities, and long-term growth prospects.</li>
</ul>
</body>
<body>
<!-- Signup Form -->
<form action="#" id="signup-form" method="post">
<input id="email" name="email" placeholder="Email Address" type="email"/>
<input type="submit" value="Sign Up"/>
</form>
<p> Reminder that AI-generated summary may be misleading or innaccurate due to malformed transcripts!</p> <br/><br/> <br/>
<!-- Footer -->
<footer id="footer">
<ul class="icons">
<li><a class="icon brands fa-twitter" href="#"><span class="label">Twitter</span></a></li>
<li><a class="icon brands fa-instagram" href="#"><span class="label">Instagram</span></a></li>
<li><a class="icon brands fa-github" href="#"><span class="label">GitHub</span></a></li>
<li><a class="icon fa-envelope" href="#"><span class="label">Email</span></a></li>
</ul>
<ul class="copyright">
<!-- <li>&copy; Untitled.</li> -->
<li>Credits for template: <a href="http://html5up.net">HTML5 UP</a></li>
</ul>
<!-- </footer> -->
<!-- Scripts -->
<script src="assets/js/main_test.js"></script>
</footer></body>
</html>